Aktie A40AS8 ZYVERSA THERAPEUTICS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen ZyVersa Therapeutics, Inc.

Aktien

A40AS8

US98987D3008

ZVSA

Markt geschlossen - Nasdaq
Andere Börsenplätze
 22:00:00 02.05.2024 		% 5 Tage % 1. Jan.
5.74 USD +9.54% Intraday Chart für ZyVersa Therapeutics, Inc. -5.51% -36.22%
25.03. ZyVersa Therapeutics, Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr CI
18.03. ZyVersa Therapeutics, Inc. gibt die Genehmigung des IRB für das Protokoll einer klinischen Phase-2A-Studie zur Bewertung des Cholesterin-Efflux-Mediators VAR 200 bei Patienten mit diabetischer Nierenerkrankung bekannt CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
ZyVersa Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
ZyVersa Therapeutics, Inc. Announces IRB Approval of Phase 2A Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator VAR 200 in Patients with Diabetic Kidney Disease
ZyVersa Therapeutics, Inc. Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option
Jobs Data in Focus as Exchange-Traded Funds Advance, Equity Futures Mixed Pre-Bell Thursday
Top Premarket Decliners
ZyVersa Prices $5 Million Offering of Common Shares, Warrants
ZyVersa Therapeutics, Inc. Announces Publication Showing AIM2 and NLRP3 Inflammasomes Promote Atherosclerosis in Diabetes, Supporting IC 100?s Rationale for Targeting ASC to Inhibit Multiple Inflammasome Pathways
Top Midday Decliners
ZyVersa Therapeutics Shares Fall Following Announcement of Reverse Stock Split, Increase in Authorized Common Shares
ZyVersa Therapeutics, Inc. Announces Reverse Stock Split and Increase in Authorized Shares of Common Stock
ZyVersa Therapeutics Reports Third Quarter 2023 Corporate Update and Financial Results
ZyVersa Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
ZyVersa Therapeutics Announces Article Published in Peer-Reviewed Biomedical Journal Demonstrating That NLRP3 Inflammasome Inhibition Attenuates Inflammatory Bowel Disease Symptoms in Animal Model
ZyVersa Therapeutics Announces Article in Peer-Reviewed Journal, Ecotoxicology and Environmental Safety, Linking Air Pollution with Development and Progression of Chronic Kidney Disease That Can Be Attenuated by Inhibiting Inflammasome NLRP3 Activation
ZyVersa Therapeutics Announces Publication in Molecular Neurobiology Reinforcing Data Demonstrating That Inflammasome ASC Inhibitor IC 100 Attenuates the Inflammatory Response Causing Neuronal Damage in Multiple Sclerosis Model, Potentially Providing Neuroprotection
ZyVersa Therapeutics, Inc. Announces Publication in Molecular Neurobiology Reinforcing Data Demonstrating that Inflammasome ASC Inhibitor IC 100 Attenuates Inflammatory Response Causing Neuronal Damage in Multiple Sclerosis Model, Potentially Providing Neuroprotection
ZyVersa Therapeutics Announces Research Published in the Peer-Reviewed Journal Diabetes Reinforcing IC 100’s Rationale for Inhibiting ASC to Attenuate Damaging Inflammation Associated with Serious Conditions Such as Obesity-related Heart Disease
ZyVersa Therapeutics, Inc. Announces Research Published in the Peer-Reviewed Journal Diabetes Reinforcing IC 100's Rationale for Inhibiting ASC to Attenuate Damaging Inflammation Associated with Serious Conditions Such as Obesity-related Heart Disease
ZyVersa Therapeutics Announces a Publication in the Peer-Reviewed Journal, Aging, Linking Inflammasome NLRP3 Activation with Age-Related Structural Changes in the Kidney and Reduced Kidney Function
ZyVersa Therapeutics Announces Peer-Reviewed Publication in Nature Reviews Nephrology Substantiating VAR 200’s Rationale for Mediating Transport of Cholesterol and Lipids Out of Kidney Cells to Attenuate Progression of Kidney Disease
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A40AS8 Aktie
  4. Nachrichten ZyVersa Therapeutics, Inc.
  5. Andere Sprachen